

PDCD1

Human anti-PD-1 (Cemiplimab) mAb

Catalog No.	CSB118A CSB118B	Quantity:	200 µg 1.0 mg
Alternate Names:	REGN-2810,SAR-439684,cemiplimab-rwlc, Libtayo		
Description:	Cemiplimab is fully human PD-1 antibody. The first indication for marketing application is metastatic / local advanced squamous cell carcinoma (Cutaneous Squamous Cell Carcinoma, CSCC). It is an intravenous immunotherapy, acting as a checkpoint inhibitor, targeting the PD-1/PD-L1 pathway, increasing the immune response to cancer cells.		
Concentration:	1.0 mg/ml		
UniProt ID (target):	Q15116		
Source:	CHO cell line		
Isotype:	Human IgG4 kappa		
INN:	Cemiplimab		
Specificity:	Human PD-1		
Biologic Activity:	Binds to PD-1 and block the PD-1/PD-L1 pathway; checkpoint inhibitor		
Formulation:	PBS, pH 7.5		
Purity:	> 95% as determined by SDS-PAGE		
Reactivity:	Human		
Applications:	Functional studies, ELISA		
Storage & Stability:	Recommended storage, undiluted at 2-8°C for up to 1 week, or in working aliquots at -20°C to -80°C for up to 1 year. Avoid freeze/thaw cycles.		

NOT FOR HUMAN USE. FOR RESEARCH ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.



Cell Sciences®
65 Parker Street
Unit 11
Newburyport, MA 01950

Toll Free: 888-769-1246
Phone: 978-572-1070
Fax: 978-992-0298

E-mail: info@cellsciences.com
Website: www.cellsciences.com